Aisling Capital as of Sept. 30, 2014
Portfolio Holdings for Aisling Capital
Aisling Capital holds 18 positions in its portfolio as reported in the September 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Zeltiq Aesthetics | 11.4 | $59M | 2.6M | 22.63 | |
| Esperion Therapeutics (ESPR) | 9.8 | $50M | 2.1M | 24.46 | |
| T2 Biosystems | 8.8 | $46M | 2.5M | 18.09 | |
| Loxo Oncology | 8.8 | $45M | 3.5M | 13.13 | |
| Catalent (CTLT) | 8.6 | $44M | 1.8M | 25.03 | |
| Chimerix (CMRX) | 8.2 | $42M | 1.5M | 27.62 | |
| Versartis | 7.3 | $38M | 2.0M | 18.99 | |
| Transenterix | 7.0 | $36M | 8.3M | 4.36 | |
| Cempra | 7.0 | $36M | 3.3M | 10.96 | |
| Durata Therapeutics | 5.0 | $26M | 2.0M | 12.68 | |
| Ambit Bioscience | 4.9 | $25M | 1.7M | 15.40 | |
| Agile Therapeutics | 3.1 | $16M | 2.2M | 7.30 | |
| Pernix Therapeutics Holdings | 3.0 | $15M | 2.0M | 7.68 | |
| Roka Bioscience | 2.2 | $11M | 1.1M | 10.05 | |
| Sorrento Therapeutics (SRNEQ) | 1.6 | $8.0M | 1.8M | 4.52 | |
| Lombard Med (EVARF) | 1.3 | $6.8M | 886k | 7.69 | |
| Intersect Ent | 1.1 | $5.4M | 350k | 15.51 | |
| Mei Pharma | 1.0 | $5.3M | 762k | 6.90 |
